Andra AP fonden Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Andra AP fonden boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 583.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 28,912 shares of the biopharmaceutical company’s stock after purchasing an additional 24,680 shares during the period. Andra AP fonden’s holdings in Regeneron Pharmaceuticals were worth $18,028,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp raised its position in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the last quarter. Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 10.7% during the 2nd quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock worth $27,371,000 after purchasing an additional 4,244 shares during the period. National Pension Service raised its stake in shares of Regeneron Pharmaceuticals by 2.2% during the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock worth $236,830,000 after buying an additional 8,264 shares in the last quarter. Krensavage Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the second quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company’s stock valued at $3,741,000 after buying an additional 2,000 shares in the last quarter. Finally, Engineers Gate Manager LP raised its position in Regeneron Pharmaceuticals by 4,309.4% in the second quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company’s stock worth $9,926,000 after acquiring an additional 15,557 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on REGN shares. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. HSBC raised their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Truist Financial upped their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $802.18.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the transaction, the executive vice president owned 12,003 shares of the company’s stock, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock valued at $3,432,488 in the last ninety days. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ:REGN traded up $9.15 during midday trading on Tuesday, reaching $807.32. The company’s stock had a trading volume of 244,562 shares, compared to its average volume of 829,892. The firm has a market cap of $83.12 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 1.54 and a beta of 0.20. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $859.34. The business has a 50 day moving average price of $769.53 and a 200 day moving average price of $720.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business posted $12.81 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.